

PUBLISHED INFORMATION REQUEST

Reference: 13604
Description: Pharmacy - Patient Drugs + MS

Response

I am analysing the treatment of neurology patients within secondary care. Could you please answer the following two questions:

Data period 01/07/2020 – 31/12/2020

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

Aubagio (teriflunomide) - 0
Avonex (interferon beta-1a) - 0
Betaferon (interferon beta-1b) - 0
Brabio (glatiramer acetate) - 0
Copaxone (glatiramer acetate) - 0
Extavia (beta interferon-1b) - 0
Fampyra (fampridine) - 0
Gilenya (fingolimod) - 0
Lemtrada (alemtuzumab) - 0
Mavenclad (cladribine) - 0
Mayzent (siponimod) - 0
Ocrevus (ocrelizumab) - 35
Plegridy (peginterferon beta-1a) - 0
Rebif (beta interferon-1a) - 0
Tecfidera (dimethyl fumarate) - 0
Tysabri (natalizumab) - 21
Zeposia (ozanimod) - 0

2. How many patients have been treated in the past 6 months for the following conditions:
Multiple Sclerosis (any type)

Relapsing remitting multiple sclerosis (RRMS)
Secondary progressive multiple sclerosis (SPMS)
Primary progressive multiple sclerosis (PPMS)

Trust Headquarters:
Westmorland General Hospital
Burton Road
Kendal
LA9 7RG
Tel: 01539 716621

CHAIR: PROFESSOR MIKE THOMAS
CHIEF EXECUTIVE: AARON CUMMINS

I can confirm that the Trust does not hold this information as neurology services, within the Trust, are provided by third party providers. At Furness General Hospital this service is provided by Cumbria Partnership NHS Foundation Trust and at the Royal Lancaster Infirmary by Lancashire Teaching Hospitals NHS Foundation Trust.